Clinical trials: Induction Chemotherapy
Chemotherapy-induced Thrombocytopenia
Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia
To evaluate the efficacy and safety of QL0911 in Chemotherapy- Induced Thrombocytopenia. Thrombocytopenia is a low number of platelets in the blood. Sometimes, thrombocytopenia is a side effect of chemotherapy.
- Trial name
- NCT05851027
- Testing
- QL0911
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Oncology, Chemotherapy-Induced Peripheral Neuropathy
8 Weeks vs 12 Weeks Physical Exercise Programmes in Colorectal Cancer Patients
Chemotherapy is a cornerstone in the treatment of colon cancer; however, its effects extend beyond malignant cells. Because chemotherapeutic agents target rapidly dividing cells, they can also damage healthy tissues, resulting in…
- Trial name
- NCT07307690
- Testing
- Exercise, Physical activity recommendations
- Volunteers
- 50 people
- Sponsor
- University of Salamanca
Breast Cancer, Breast Cancer Stage I
Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients
This study is being done to determine if using the Paxman Scalp Cooling System at temperatures lower than the current standard is a safe and tolerable approach to prevent hair loss in breast cancer patients receiving chemotherapy.
- Conditions
- Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
- Trial name
- NCT04180579
- Testing
- PAXMAN Scalp Cooler
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chemotherapy-induced Peripheral Neuropathy, Pediatric Cancer
Preventing Sensory and Motor Dysfunctions in Children Receiving Neurotoxic Chemotherapy
The investigators would like to conduct a prospective, multicenter, two-armed trial (RCT with follow-up). Patients will be recruited from 7 centers (CH/D).
- Trial name
- PrepAIR (NCT05606588)
- Testing
- Playful sensorimotor training
- Where
- 2 sites in Switzerland
- Volunteers
- 131 people
- Sponsor
- University of Basel
Head and Neck Cancer
Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients
The purpose of this study is to determine 1-year survival of previously irradiated Head and Neck cancer (HNC) patients with loco-regional recurrent disease treated with induction chemotherapy with pemetrexed and gemcitabine…
- Trial name
- NCT01172470
- Testing
- Gemcitabine, Pemetrexed, Carboplatin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Chicago
Nasopharyngeal Carcinoma
Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal Carcinoma
The investigators aim to evaluate the survival benefit from triple combination of induction, concurrent and aduvant chemotherapy versus concurrent chemotherapy alone for high risk locoregionally advanced nasopharyngeal carcinoma…
- Trial name
- NCT02621970
- Testing
- Cisplatin 1, Cisplatin 2, Docetaxel
- Where
- China
- Volunteers
- 534 people
- Sponsor
- Sun Yat-sen University
Alcohol Use Disorder (AUD)
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
The goal of this research is to replicate findings previously conducted in a pilot trial and to understand, mechanistically, the role of stress in the development of AUD pharmacotherapies that target noradrenergic blockade.
- Trial name
- DOXY (NCT04135846)
- Testing
- Doxazosin
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- Brown University
Thrombopenia, Cervical Cancer
Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer
Exploring and evaluating the efficacy of herombopag in preventing thrombocytopenia due to radiotherapy for cervical cancer
- Conditions
- Thrombopenia, Cervical Cancer, Radiotherapy Side Effect, Chemotherapeutic Toxicity
- Trial name
- NCT06745219
- Testing
- herombopag
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Peripheral Nervous System Diseases, Chemotherapy-Induced Peripheral Neuropathy
Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy
This study will assess the safety and efficacy of Neotrofin in treating the peripheral neuropathy that results from chemotherapy for cancer.
- Trial name
- NCT00041795
- Testing
- leteprinim potassium (Neotrofin)
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- NeoTherapeutics
Inborn Errors of Metabolism
Induced Pluripotent Stem Cells for the Development of Novel Drug Therapies for Inborn Errors of Metabolism (iPSC-IEM)
Human induced pluripotent stem cells (iPSCs), are reprogrammed from somatic cells that can self-renew indefinitely and produce different types of cells. They provide human model cell lines for orphan drug development.
- Trial name
- iPSC-IEM (NCT04097275)
- Testing
- Skin biopsy, Withdraw of blood
- Where
- Pakistan
- Volunteers
- 1,000 people
- Sponsor
- CENTOGENE GmbH Rostock
Lung Cancer, Neurotoxicity
Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more tumor cells.
- Conditions
- Lung Cancer, Neurotoxicity, Ovarian Cancer
- Trial name
- NCT00003072
- Testing
- amifostine trihydrate, carboplatin, paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- University of California, San Francisco
Alcohol Dependence
Prometa Protocol for Alcohol Dependence
This is a placebo controlled trial (some people receive active and some people receive inactive medication) to evaluate the effectiveness of a new protocol to treat alcohol dependence.
- Trial name
- NCT00262639
- Testing
- Flumazenil and Gabapentin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Medical University of South Carolina
Lung Cancer
Combination Chemotherapy as Induction Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003037
- Testing
- cisplatin, docetaxel, gemcitabine hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasm, Colorectal, Cognitive Impairment
Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
The purpose of this research study is to see how the brain changes in patients receiving chemotherapy (cytotoxic drug) treatment for colon or rectal cancer at Parkview Cancer Institute.
- Conditions
- Neoplasm, Colorectal, Cognitive Impairment, Cognitive Dysfunction, Cognitive Change
- Trial name
- Chemo Brain (NCT05014399)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Joseph McCollom
Permanent Chemotherapy-induced Alopecia
Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia
An open label, pilot study involving the use of low dose oral minoxidil to treat permanent chemotherapy-induced alopecia.
- Trial name
- NCT03831334
- Testing
- oral minoxidil
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Northwestern University
Non-small Cell Lung Cancer Stage III
Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC
Standard treatment for stage III Non-Small Cells Lung Cancer (NSCLC) not eligibile for surgery is concomitant chemoradiotherapy.
- Trial name
- BRIDGE (NCT04765709)
- Testing
- durvalumab plus platinum-based chemotherapy (cisplatin or carboplatin plus vinorelbine or pemetrexed), Durvalumab plus radiotherapy, durvalumab
- Where
- 3 sites in France, Italy and 1 more
- Volunteers
- 10 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Cancer, Pediatrics
SPOG 2015 FN Definition. A Multi-center Non-inferiority Trial on Safety of a High Versus Low Temperature Limit Defining Fever in Pediatric Patients With Cancer at Risk for Fever in Chemotherapy-induced Neutropenia
In a multi-center open-label cluster-randomized controlled parallel-group multiple crossover non-inferiority trial in children and adolescents up to 20 years diagnosed with cancer requiring chemotherapy, primarily the safety, and…
- Conditions
- Cancer, Pediatrics, Fever, Neutropenia
- Trial name
- NCT02324231
- Testing
- 39.0°C temperature limit defining fever, 38.5°C temperature limit defining fever
- Where
- 6 sites in Switzerland
- Volunteers
- 269 people
- Sponsor
- Swiss Pediatric Oncology Group
Rectal Cancer, Liver Metastases
Preoperative CRT With or Without Induction Chemotherapy for Rectal Cancer With Liver Metastases
To investigate the feasibility of preoperative chemoradiation with oxaliplatin plus capecitabine, with or without prior induction chemotherapy in patients with locally advanced or marginally resectable rectal cancer with…
- Trial name
- NCT01643070
- Testing
- Capecitabine, Oxaliplatin, Radiotherapy
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Asan Medical Center
Pulmonary Neoplasms
Study of Preoperative Docetaxel or Cisplatin (CDDP) + Docetaxel for C-stage IB-II Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the safety and efficacy of the preoperative docetaxel and docetaxel-cisplatin combination in c-stage IB/II NSCLC, and select the optimal preoperative therapy for phase III trials.
- Trial name
- NCT00132639
- Testing
- Preoperative docetaxel-cisplatin combination chemotherapy, Preoperative docetaxel monotherapy
- Where
- Japan
- Volunteers
- 80 people
- Sponsor
- Haruhiko Fukuda
Oral Mucositis, Carcinoma in Situ of Upper Respiratory Tract
Efficacy of MUCIPLIQ on the Incidence of Radio-chemotherapy-induced Mucositis in Patients Suffering From Oral Cancer
MUCIPLIQ is a nanopolymer engineered to mimic glycosaminoglycans such as heparan sulfates. Glycosaminoglycans are involved 1) in the stabilization of cells micro-environment, known as extracellular matrix, by binding to…
- Trial name
- MUCIPLIQ (NCT01840436)
- Testing
- MUCIPLIQ
- Where
- 5 sites in France
- Volunteers
- 136 people
- Sponsor
- Organ, Tissue, Regeneration, Repair and Replacement
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.